Hilar cholangiocarcinoma: Current management

Annals of Surgery

Volumn 250, Issue 2, 2009, Pages 210-218

  Ito, Fumito ^a   Cho, Clifford S ^a   Rikkers, Layton F ^a   Weber, Sharon M ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

Hilar cholangiocarcinoma; Liver resection; Orthotopic liver transplantation

Indexed keywords

ARTIFICIAL EMBOLISM; BILE DUCT CARCINOMA; HILAR CHOLANGIOCARCINOMA; HUMAN; KLATSKIN TUMOR; LAPAROSCOPY; LIVER RESECTION; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; PORTAL VEIN; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; BILE DUCT TUMOR; HEPATIC DUCT; MORTALITY; PATHOLOGY; WOUND DRAINAGE;

BILE DUCT NEOPLASMS; DRAINAGE; HEPATECTOMY; HEPATIC DUCT, COMMON; HUMANS; KLATSKIN'S TUMOR; LAPAROSCOPY; LIVER TRANSPLANTATION;

EID: 68949088652     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181afe0ab     Document Type: Review

References (138)

1. Altmeier WA, Gall EA, Zinninger MM, et al. Sclerosing carcinoma of the major intrahepatic bile ducts. AMA Arch Surg. 1957;75:450-460.
2. Klastskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med. 1965;38:241-256.
3. Bismuth H, Castaing D, Traynor O. Resection or palliation: priority of surgery in the treatment of hilar cancer. World J Surg. 1988;12:39-47.
4. Bismuth H, Malt RA. Current concepts in cancer: carcinoma of the biliary tract. N Engl J Med. 1979;301:704-706.
5. Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet. 1975;140:170-178.
6. Tompkins RK, Thomas D, Wile A, et al. Prognostic factors in bile duct carcinoma: analysis of 96 cases. Ann Surg. 1981;194:447-457.
7. Beazley RM, Hadjis N, Benjamin IS, et al. Clinicopathological aspects of high bile duct cancer. Experience with resection and bypass surgical treatments. Ann Surg. 1984;199:623-636.
8. Kosuge T, Yamamoto J, Shimada K, et al. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg. 1999;230:663-671.
9. Neuhaus P, Jonas S, Bechstein WO, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg. 1999;230:808-818.
10. Launois B, Reding R, Lebeau G, et al. Surgery for hilar cholangiocarcinoma: French experience in a collective survey of 552 extrahepatic bile duct cancers. J Hepatobiliary Pancreat Surg. 2000;7:128-134.
11. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001; 234:507-517.
12. Seyama Y, Kubota K, Sano K, et al. Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann Surg. 2003;238:73-83.
13. Weinbren K, Mutum SS. Pathological aspects of cholangiocarcinoma. J Pathol. 1983;139:217-238.
14. Hayashi S, Miyazaki M, Kondo Y, et al. Invasive growth patterns of hepatic hilar ductal carcinoma. A histologic analysis of 18 surgical cases. Cancer. 1994;73:2922-2929.
15. Jarnagin WR, Bowne W, Klimstra DS, et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg. 2005;241:703-712.
16. Shimada H, Niimoto S, Matsuba A, et al. The infiltration of bile duct carcinoma along the bile duct wall. Int Surg. 1988;73:87-90.
17. Sakamoto E, Nimura Y, Hayakawa N, et al. The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg. 1998;227:405-411.
18. Hadjis NS, Blumgart LH. Role of liver atrophy, hepatic resection and hepatocyte hyperplasia in the development of portal hypertension in biliary disease. Gut. 1987;28:1022-1028.
19. Burke EC, Jarnagin WR, Hochwald SN, et al. Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg. 1998;228:385-394.
20. Nimura Y, Hayakawa N, Kamiya J, et al. Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus. World J Surg. 1990;14:535-543.
21. Mizumoto R, Kawarada Y, Suzuki H. Surgical treatment of hilar carcinoma of the bile duct. Surg Gynecol Obstet. 1986;162:153-158.
22. Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg. 2001;233:385-392.
23. Ito F, Agni R, Rettammel RJ, et al. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg. 2008; 248:273-279.
24. Verbeek PC, van Leeuwen DJ, de Wit LT, et al. Benign fibrosing disease at the hepatic confluence mimicking Klatskin tumors. Surgery. 1992;112: 866-871.
25. Wetter LA, Ring EJ, Pellegrini CA, et al. Differential diagnosis of sclerosing cholangiocarcinomas of the common hepatic duct (Klatskin tumors). Am J Surg. 1991;161:57-62.
26. Saini S. Imaging of the hepatobiliary tract. N Engl J Med. 1997;336:1889-1894.
27. Gibson RN, Yeung E, Thompson JN, et al. Bile duct obstruction: radiologic evaluation of level, cause, and tumor resectability. Radiology. 1986;160:43-47.
28. Hann LE, Greatrex KV, Bach AM, et al. Cholangiocarcinoma at the hepatic hilus: sonographic findings. Am J Roentgenol. 1997;168:985-989.
29. Okuda K, Ohto M, Tsuchiya Y. The role of ultrasound, percutaneous transhepatic cholangiography, computed tomographic scanning, and magnetic resonance imaging in the preoperative assessment of bile duct cancer. World J Surg. 1988;12:18-26.
30. Manfredi R, Barbaro B, Masselli G, et al. Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis. 2004;24:155-164.
31. Yeh TS, Jan YY, Tseng JH, et al. Malignant perihilar biliary obstruction: magnetic resonance cholangiopancreatographic findings. Am J Gastroenterol. 2000;95:432-440.
32. Zhang Y, Uchida M, Abe T, et al. Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI. J Comput Assist Tomogr. 1999;23:670-677.
33. Anderson CD, Rice MH, Pinson CW, et al. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg. 2004;8:90-97.
34. Cherqui D, Benoist S, Malassagne B, et al. Major liver resection for carcinoma in jaundiced patients without preoperative biliary drainage. Arch Surg. 2000;135:302-308.
35. Figueras J, Llado L, Valls C, et al. Changing strategies in diagnosis and management of hilar cholangiocarcinoma. Liver Transpl. 2000;6:786-794.
36. Rea DJ, Munoz-Juarez M, Farnell MB, et al. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch Surg. 2004;139: 514-523.
37. Lai EC, Mok FP, Fan ST, et al. Preoperative endoscopic drainage for malignant obstructive jaundice. Br J Surg. 1994;81:1195-1198.
38. Pitt HA, Gomes AS, Lois JF, et al. Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost? Ann Surg. 1985; 201:545-553.
39. Hochwald SN, Burke EC, Jarnagin WR, et al. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg. 1999;134:261-266.
40. Savader SJ, Trerotola SO, Merine DS, et al. Hemobilia after percutaneous transhepatic biliary drainage: treatment with transcatheter embolotherapy. J Vasc Interv Radiol. 1992;3:345-352.
41. Chapman WC, Sharp KW, Weaver F, et al. Tumor seeding from percutaneous biliary catheters. Ann Surg. 1989;209:708-713.
42. Sakata J, Shirai Y, Wakai T, et al. Catheter tract implantation metastases associated with percutaneous biliary drainage for extrahepatic cholangiocarcinoma. World J Gastroenterol. 2005;11:7024-7027.
43. Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg. 2002;137:675-680.
44. Hemming AW, Reed AI, Howard RJ, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg. 2003;237:686-691.
45. Shoup M, Gonen M, D'Angelica M, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg. 2003;7:325-330.
46. Vauthey JN, Chaoui A, Do KA, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery. 2000;127:512-519.
47. Kubota K, Makuuchi M, Kusaka K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology. 1997;26:1176-1181.
48. Shirabe K, Shimada M, Gion T, et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg. 1999;188:304-309.
49. Kinoshita H, Sakai K, Hirohashi K, et al. Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg. 1986;10:803-808.
50. Ebata T, Nagino M, Kamiya J, et al. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg. 2003;238:720-727.
51. Imamura H, Shimada R, Kubota M, et al. Preoperative portal vein embolization: an audit of 84 patients. Hepatology. 1999;29:1099-1105.
52. Makuuchi M, Thai BL, Takayasu K, et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery. 1990;107:521-527.
53. Nagino M, Kamiya J, Nishio H, et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg. 2006;243:364-372.
54. Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003;237:208-217.
55. Lee KC, Kinoshita H, Hirohashi K, et al. Extension of surgical indications for hepatocellular carcinoma by portal vein embolization. World J Surg. 1993;17:109-115. (Pubitemid 23189031)
56. Shimamura T, Nakajima Y, Une Y, et al. Efficacy and safety of preoperative percutaneous transhepatic portal embolization with absolute ethanol: a clinical study. Surgery. 1997;121:135-141. (Pubitemid 27091767)
57. Yamakado K, Takeda K, Matsumura K, et al. Regeneration of the un-embolized liver parenchyma following portal vein embolization. J Hepatol. 1997;27:871-880.
58. Azoulay D, Castaing D, Krissat J, et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg. 2000;232:665-672.
59. Elias D, Ouellet JF, De Baere T, et al. Preoperative selective portal vein embolization before hepatectomy for liver metastases: long-term results and impact on survival. Surgery. 2002;131:294-299.
60. Jaeck D, Oussoultzoglou E, Rosso E, et al. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg. 2004;240:1037-1049.
61. Katoh T, Tanaka M, Nimura Y, et al. Enhancement of rat liver mitochondrial function by portal branch ligation secures subsequent extended hepatectomy. Biochem Int. 1991;24:107-116.
62. Ozawa K, Takasan H, Kitamura O, et al. Effect of ligation of portal vein on liver mitochondrial metabolism. J Biochem. 1971;70:755-764.
63. Shimizu Y, Suzuki H, Nimura Y, et al. Elevated mitochondrial gene expression during rat liver regeneration after portal vein ligation. Hepatology. 1995;22:1222-1229.
64. Takeuchi E, Nimura Y, Mizuno S, et al. Ligation of portal vein branch induces DNA polymerases alpha, delta, and epsilon in nonligated lobes. J Surg Res. 1996;65:15-24.
65. Kawasaki S, Imamura H, Kobayashi A, et al. Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization. Ann Surg. 2003;238:84-92.
66. Kondo S, Hirano S, Ambo Y, et al. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study. Ann Surg. 2004;240:95-101.
67. Sano T, Shimada K, Sakamoto Y, et al. One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality. Ann Surg. 2006;244:240-247.
68. Vauthey JN, Pawlik TM, Abdalla EK, et al. Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg. 2004;239:722-730.
69. Weber SM, DeMatteo RP, Fong Y, et al. Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann Surg. 2002;235:392-399.
70. Connor S, Barron E, Wigmore SJ, et al. The utility of laparoscopic assessment in the preoperative staging of suspected hilar cholangiocarcinoma. J Gastrointest Surg. 2005;9:476-480.
71. Goere D, Wagholikar GD, Pessaux P, et al. Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma. Surg Endosc. 2006; 20:721-725.
72. Capussotti L, Muratore A, Polastri R, et al. Liver resection for hilar cholangiocarcinoma: in-hospital mortality and long-term survival. J Am Coll Surg. 2002;195:641-647.
73. Dinant S, Gerhards MF, Rauws EA, et al. Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor). Ann Surg Oncol. 2006;13:872-880.
74. Gazzaniga GM, Filauro M, Bagarolo C, et al. Surgery for hilar cholangio-carcinoma: an Italian experience. J Hepatobiliary Pancreat Surg. 2000;7: 122-127.
75. Gerhards MF, van Gulik TM, de Wit LT, et al. Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma-a single center experience. Surgery. 2000;127:395-404.
76. Hadjis NS, Blenkharn JI, Alexander N, et al. Outcome of radical surgery in hilar cholangiocarcinoma. Surgery. 1990;107:597-604.
77. Hasegawa S, Ikai I, Fujii H, et al. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg. 2007;31:1256-1263.
78. Hemming AW, Reed AI, Fujita S, et al. Surgical management of hilar cholangiocarcinoma. Ann Surg. 2005;241:693-699.
79. IJitsma AJ, Appeltans BM, de Jong KP, et al. Extrahepatic bile duct resection in combination with liver resection for hilar cholangiocarcinoma: a report of 42 cases. J Gastrointest Surg. 2004;8:686-694.
80. Kawarada Y, Das BC, Naganuma T, et al. Surgical treatment of hilar bile duct carcinoma: experience with 25 consecutive hepatectomies. J Gastrointest Surg. 2002;6:617-624.
81. Klempnauer J, Ridder GJ, von Wasielewski R, et al. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol. 1997;15:947-954.
82. Lee SG, Lee YJ, Park KM, et al. One hundred and eleven liver resections for hilar bile duct cancer. J Hepatobiliary Pancreat Surg. 2000;7:135-141.
83. Miyazaki M, Ito H, Nakagawa K, et al. Aggressive surgical approaches to hilar cholangiocarcinoma: hepatic or local resection? Surgery. 1998;123: 131-136. (Pubitemid 28110073)
84. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224:463-473.
85. Nimura Y, Kamiya J, Kondo S, et al. Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J Hepatobiliary Pancreat Surg. 2000;7:155-162.
86. Su CH, Tsay SH, Wu CC, et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg. 1996;223:384-394.
87. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685-1695.
88. Todoroki T, Kawamoto T, Koike N, et al. Radical resection of hilar bile duct carcinoma and predictors of survival. Br J Surg. 2000;87:306-313.
89. Hemming AW, Kim RD, Mekeel KL, et al. Portal vein resection for hilar cholangiocarcinoma. Am Surg. 2006;72:599-604.
90. Tsao JI, Nimura Y, Kamiya J, et al. Management of hilar cholangiocarci-noma: comparison of an American and a Japanese experience. Ann Surg. 2000;232:166-174.
91. Abdel WM, Fathy O, Elghwalby N, et al. Resectability and prognostic factors after resection of hilar cholangiocarcinoma. Hepatogastroenterology. 2006;53:5-10.
92. Lai EC, Lau WY. Aggressive surgical resection for hilar cholangiocarcinoma. ANZ J Surg. 2005;75:981-985.
93. Nakeeb A, Tran KQ, Black MJ, et al. Improved survival in resected biliary malignancies. Surgery. 2002;132:555-563.
94. Havlik R, Sbisa E, Tullo A, et al. Results of resection for hilar cholangio-carcinoma with analysis of prognostic factors. Hepatogastroenterology. 2000;47:927-931.
95. Baton O, Azoulay D, Adam DV, et al. Major hepatectomy for hilar cholangiocarcinoma type 3 and 4: prognostic factors and longterm outcomes. J Am Coll Surg. 2007;204:250-260.
96. Jarnagin WR, Shoup M. Surgical management of cholangiocarcinoma. Semin Liver Dis. 2004;24:189-199.
97. Park SW, Park YS, Chung JB, et al. Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection. Hepatogastroenterology. 2004;51:1612-1618.
98. Ikeyama T, Nagino M, Oda K, et al. Surgical approach to bismuth Type I and II hilar cholangiocarcinomas: audit of 54 consecutive cases. Ann Surg. 2007;246:1052-1057.
99. Jang JY, Kim SW, Park DJ, et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg. 2005;241:77-84.
100. Ogura Y, Mizumoto R, Tabata M, et al. Surgical treatment of carcinoma of the hepatic duct confluence: analysis of 55 resected carcinomas. World J Surg. 1993;17:85-92.
101. Sugiura Y, Nakamura S, Iida S, et al. Extensive resection of the bile ducts combined with liver resection for cancer of the main hepatic duct junction: a cooperative study of the Keio Bile Duct Cancer Study Group. Surgery. 1994;115:445-451.
102. Gazzaniga GM, Ciferri E, Bagarolo C, et al. Primitive hepatic hilum neoplasm. J Surg Oncol Suppl. 1993;3:140-146.
103. Miyazaki M, Kato A, Ito H, et al. Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not? Surgery. 2007;141:581-588.
104. Munoz L, Roayaie S, Maman D, et al. Hilar cholangiocarcinoma involving the portal vein bifurcation: long-term results after resection. J Hepatobiliary Pancreat Surg. 2002;9:237-241.
105. Tabata M, Kawarada Y, Yokoi H, et al. Surgical treatment for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2000;7:148-154.
106. Andersen JR, Sorensen SM, Kruse A, et al. Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut. 1989;30:1132-1135.
107. Lai EC, Chu KM, Lo CY, et al. Choice of palliation for malignant hilar biliary obstruction. Am J Surg. 1992;163:208-212.
108. Prat F, Chapat O, Ducot B, et al. Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline. Gut. 1998;42:76-80.
109. Shepherd HA, Royle G, Ross AP, et al. Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: a randomized trial. Br J Surg. 1988;75:1166-1168.
110. Smith AC, Dowsett JF, Russell RC, et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet. 1994;344:1655-1660.
111. Cheng JL, Bruno MJ, Bergman JJ, et al. Endoscopic palliation of patients with biliary obstruction caused by nonresectable hilar cholangiocarcinoma: efficacy of self-expandable metallic Wallstents. Gastrointest Endosc. 2002; 56:33-39.
112. De Palma GD, Pezzullo A, Rega M, et al. Unilateral placement of metallic stents for malignant hilar obstruction: a prospective study. Gastrointest Endosc. 2003;58:50-53.
113. Freeman ML, Overby C. Selective MRCP and CT-targeted drainage of malignant hilar biliary obstruction with self-expanding metallic stents. Gastrointest Endosc. 2003;58:41-49.
114. Becker CD, Glattli A, Maibach R, et al. Percutaneous palliation of malignant obstructive jaundice with the Wallstent endoprosthesis: follow-up and rein-tervention in patients with hilar and non-hilar obstruction. J Vasc Interv Radiol. 1993;4:597-604.
115. Cheung KL, Lai EC. Endoscopic stenting for malignant biliary obstruction. Arch Surg. 1995;130:204-207.
116. De Palma GD, Galloro G, Siciliano S, et al. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc. 2001;53:547-553.
117. Davids PH, Groen AK, Rauws EA, et al. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet. 1992;340:1488-1492.
118. Kaassis M, Boyer J, Dumas R, et al. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc. 2003;57:178-182.
119. Knyrim K, Wagner HJ, Pausch J, et al. A prospective, randomized, controlled trial of metal stents for malignant obstruction of the common bile duct. Endoscopy. 1993;25:207-212.
120. McCaughan JS Jr, Mertens BF, Cho C, et al. Photodynamic therapy to treat tumors of the extrahepatic biliary ducts. A case report. Arch Surg. 1991; 126:111-113.
121. Berr F, Wiedmann M, Tannapfel A, et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology. 2000;31:291-298.
122. Dumoulin FL, Gerhardt T, Fuchs S, et al. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc. 2003;57:860-867.
123. Ortner MA, Liebetruth J, Schreiber S, et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology. 1998;114:536-542.
124. Rumalla A, Baron TH, Wang KK, et al. Endoscopic application of photodynamic therapy for cholangiocarcinoma. Gastrointest Endosc. 2001;53: 500-504.
125. Wiedmann M, Berr F, Schiefke I, et al. Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest Endosc. 2004;60:68-75.
126. Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology. 2003;125:1355-1363. (Pubitemid 37409755)
127. Zoepf T, Jakobs R, Arnold JC, et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol. 2005;100:2426-2430.
128. Goldstein RM, Stone M, Tillery GW, et al. Is liver transplantation indicated for cholangiocarcinoma? Am J Surg. 1993;166:768-771.
129. Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg. 1997;225:472-481.
130. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation. 2000;69:1633-1637.
131. Robles R, Figueras J, Turrion VS, et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg. 2004;239:265-271.
132. Shimoda M, Farmer DG, Colquhoun SD, et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl. 2001;7:1023-1033.
133. Baron TH, Harewood GC, Rumalla A, et al. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol. 2004;2:214-219.
134. Kipp BR, Stadheim LM, Halling SA, et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol. 2004;99:1675-1681.
135. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoad-juvant chemoradiation is more effective than resection for hilar cholangio-carcinoma. Ann Surg. 2005;242:451-458.
136. Heimbach JK, Gores GJ, Haddock MG, et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation. 2006;82: 1703-1707.
137. Rosen CB, Nagorney DM, Wiesner RH, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg. 1991;213:21-25.
138. Marsh JW Jr, Iwatsuki S, Makowka L, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. Ann Surg. 1988;207:21-25. (Pubitemid 18057267)